Loading
MMP9 (Matrix metalloproteinase-9) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Bevacizumab.
In plain words · MMP9 (Matrix metalloproteinase-9) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
MMP9 (Matrix metalloproteinase-9) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption.
No product in this corpus aims at MMP9 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MMP9: RNA group enriched (bone marrow 356 nTPM, lymphoid tissue 103 nTPM); blood lineage lineage enriched (granulocytes 273 nTPM); high antibody staining in 3 normal tissues. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MMP9 tissue; Open Targets ENSG00000100985 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Wilhelm S.M. et al, J. Biol. Chem, 1989, "SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages". Source.
Sources: HGNC HGNC:7176 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P14780 (protein name, function text, keywords and locations (REST API)); CIViC gene MMP9 (1 evidence items, 0 assertions, 1 variants; diseases: Inflammatory Breast Carcinoma (GraphQL API, CC0))
Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves NINJ1 to generate the Secreted ninjurin-1 form. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 20q13.12 (HGNC).
RNA: group enriched (bone marrow 356 nTPM, lymphoid tissue 103 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 273 nTPM).
Medium: Appendix, Colon, Lymph node, Rectum, Testis, Tonsil.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MMP9" OR ABSTRACT:"MMP9" OR TITLE:"matrix metallopeptidase 9" OR ABSTRACT:"matrix metallopeptidase 9" OR TITLE:"Matrix metalloproteinase-9" OR ABSTRACT:"Matrix metalloproteinase-9" OR TITLE:"CLG4B" OR ABSTRACT:"CLG4B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MMP9, not a curated reading list.